Christa Noehammer,
Senior Scientist,
Austrian Institute of Technology
Christa Noehammer currently works as Senior Scientist at the Austrian Institute of Technology where she has been heading the Molecular Medicine research unit for several years. Holding a master degree in Microbiology and a PhD in Biochemistry she has been working in the microarray field since 1999 being involved in the design, production and data analysis of various microarray types thereby mainly focusing on minimally invasive biomarker discovery for cancer diagnostics. The last couple of years Dr. Noehammer has been very much involved in the setup of sampling - and biomarker isolation protocols as well as high throughput biomarker technologies for saliva diagnostics. Most recently she also started to work on saliva- and serum-derived exosomes aiming among others for the discovery of exosomal epigenetic biomarkers for early diagnosis of type 2 diabetes.
Exosome-derived Epigenetic Biomarkers For Saliva Diagnostics
Friday, 26 October 2018 at 12:00
Add to Calendar ▼2018-10-26 12:00:002018-10-26 13:00:00Europe/LondonExosome-derived Epigenetic Biomarkers For Saliva DiagnosticsExosomes and Liquid Biopsies Europe 2018 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
The aim of our research activities at AIT, the Austrian Institute of Technology, is to define reliable biomarkers suitable for early and non-invasive disease diagnosis and prognosis. To this end we have been establishing and optimizing a whole range of multiplex capability technologies (e.g. microarrays, quantitative PCR, Luminex bead technology) to meet the special demands and challenges of diagnostic biomarker discovery - and validation in body fluids. Using this specific technology expertise we e.g. successfully discovered autoantibody- as well as DNA methylation -based diagnostic marker panels for the big 4 cancer entities (breast, colon, prostate, lung) in serum or plasma. Based on these success stories and the evident advantages of saliva as a diagnostic matrix our recent special interest is to go for saliva diagnostics and to evaluate saliva for its suitability for circulating biomarker-based diagnostics. Along these lines we will report on the evaluation of different commercially available strategies for isolation of exosomes from human serum and saliva. We will further present data from genome-wide microRNA – as well as DNA-methylation profiling in salivary - and serum-derived exosomes which will also include our experiences when comparing the performance of high-density microarrays and next generation sequencing for miRNA profiling. Last but not least we will report on first salivary and plasma exosome-derived epigenetic biomarkers for type 2 diabetes diagnosis.
Add to Calendar ▼2018-10-24 00:00:002018-10-26 00:00:00Europe/LondonExosomes and Liquid Biopsies Europe 2018Exosomes and Liquid Biopsies Europe 2018 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2018-10-26 12:00:002018-10-26 13:00:00Europe/LondonExosome-derived Epigenetic Biomarkers For Saliva DiagnosticsExosomes and Liquid Biopsies Europe 2018 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
